Pages that link to "Q36833557"

The following pages link to The myelodysplastic syndrome as a prototypical epigenetic disease (Q36833557):

Displaying 39 items.

• Epigenetic Control of Haematopoietic Stem Cell Aging and Its Clinical Implications (Q26774949) (← links)
• Epigenetic regulation of hematopoietic stem cell aging (Q27026054) (← links)
• Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome (Q34628707) (← links)
• Potential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome. (Q35016534) (← links)
• Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis (Q35156907) (← links)
• Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia. (Q35745087) (← links)
• Epigenetic Control of Stem Cell Potential during Homeostasis, Aging, and Disease (Q35747943) (← links)
• BMI1 reprogrammes histone acetylation and enhances c-fos pathway via directly binding to Zmym3 in malignant myeloid progression (Q35867819) (← links)
• Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. (Q35911998) (← links)
• Epigenetic synergy between decitabine and platinum derivatives (Q36053915) (← links)
• Perspectives and future directions for epigenetics in hematology (Q36962664) (← links)
• Dpy30 is critical for maintaining the identity and function of adult hematopoietic stem cells (Q37346666) (← links)
• The genetic basis of myelodysplasia and its clinical relevance (Q37390236) (← links)
• Standardizing the initial evaluation for myelodysplastic syndromes (Q38157706) (← links)
• Myelodysplastic syndromes in the United States: an update for clinicians (Q38203323) (← links)
• Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution (Q38218055) (← links)
• The role of microRNA in myelodysplastic syndromes: beyond DNA methylation and histone modification. (Q38698438) (← links)
• Transgenerational transmission of systemic mast cell activation disease-genetic and epigenetic features (Q38735112) (← links)
• Hydroquinone-induced FOXP3-ADAM17-Lyn-Akt-p21 signaling axis promotes malignant progression of human leukemia U937 cells (Q39680352) (← links)
• Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome (Q41191920) (← links)
• Polycomb Repressor Complex 2 in Genomic Instability and Cancer (Q41573279) (← links)
• Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies (Q42421291) (← links)
• Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome (Q51439959) (← links)
• The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies. (Q53008515) (← links)
• Apoptosis in human myelodysplastic syndrome CD34+ cells is modulated by the upregulation of TLRs and histone H4 acetylation via a β-arrestin 1 dependent mechanism. (Q55059498) (← links)
• Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy (Q57795839) (← links)
• Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis (Q58706592) (← links)
• Pharmacological Reactivation of the Silenced Gene as a Targeted Therapeutic Approach for Fragile X Syndrome (Q64245000) (← links)
• Methylation level of Rap1GAP and the clinical significance in MDS. (Q64988943) (← links)
• Effect of Qinghuang Powder () Combined with Bupi Yishen Decoction () in Treating Patients with Refractory Cytopenia with Multilineage Dysplasia through Regulating DNA Methylation (Q87944354) (← links)
• Expression Profiles of DNA Methylation and Demethylation Machinery Components in Pediatric Myelodysplastic Syndrome: Clinical Implications (Q90217192) (← links)
• DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes (Q90465671) (← links)
• The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome (Q90510627) (← links)
• Traditional Chinese Medicine Containing Arsenic Treated MDS Patients Effectively through Regulating Aberrant Hypomethylation (Q90670891) (← links)
• Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome (Q90744801) (← links)
• Hypomethylation of MIR-378 5'-flanking region predicts poor survival in young patients with myelodysplastic syndrome (Q91946327) (← links)
• Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution (Q92313036) (← links)
• Role of 4‑aminobutyrate aminotransferase (ABAT) and the lncRNA co‑expression network in the development of myelodysplastic syndrome (Q92582517) (← links)
• Characteristics of myeloid sarcoma in mice and patients with TET2 deficiency (Q94552590) (← links)